FONT-SIZE Plus   Neg

Enzo Biochem Presents New AmpiProbe Nucleic Acid Amplification Platform Details

Enzo Biochem Inc. (ENZ) announced that it has made its first peer-reviewed presentation of its novel AmpiProbe platform, encompassing low cost, and high sensitivity, real time nucleic acid amplification and detection assays, at the annual meeting in London of the European Society of Clinical Microbiology and Infectious Diseases or ESCMID.

The company said its presentation, titled "Quantitative Detection of HCV RNA in Human Plasma-Serum using the Enzo AmpiProbe HCV RNA Assay," detailed the specifications and performance characteristics of the first diagnostic product developed utilizing the AmpiProbe platform.

Enzo's AmpiProbe Hepatitis C virus RNA assay was tested over hundreds of clinical samples and found to be reproducible, accurate and precise, the presentation indicated. In addition, the AmpiProbe HCV RNA assay was found, as compared to similar diagnostics products, to achieve a greater enhanced sensitivity that allows for a more convenient and efficient workflow requiring significantly less starting material.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Consumer goods giant Procter & Gamble Co. on Tuesday reported a 4 percent increase in profit for the first quarter from last year on a slight decline in sales. However, both revenue and core earnings per share for the quarter beat analysts' estimates. In addition, the company affirmed its financial outlook for fiscal 2017. Merck & Co. Inc. (MRK) reported a profit for the third-quarter that increased about 20 percent, while quarterly worldwide sales grew 5 percent. The company raised its full-year 2016 outlook. Drug maker Eli Lilly and Co. reported Tuesday lower profit in its third quarter, despite higher revenues. Adjusted earnings per share and top line missed analysts' estimates. Further, for fiscal 2016, the company trimmed its forecast for reported earnings, while maintained adjusted earnings view, and raised revenue forecast.
comments powered by Disqus
Follow RTT